“Senior citizens are facing increasing and often significant burdens from rising out-of-pocket costs on drugs that they need to improve their health while many observers worry about the long run stability of the Part D program. As part of the Prescription Drug Pricing Reduction Act (PDPRA), the Senate Finance Committee is considering two significant reforms to the Medicare Part D program aimed at reducing overall program outlays and beneficiary out-of-pocket spending. Most notably, the proposal would substantially redesign the structure of the Part D benefit to encourage more efficient management of drug spending and reduce incentives that encourage rapid growth of list prices. In addition, it would establish mandatory rebates in Medicare Part D if list prices on drugs grow faster than the rate of inflation (as measured by CPI-U) to reduce enrollee out-of-pocket spending.”
Chris Miller, Tufts Fletcher School associate professor and ‘Chip War’ author, joins ‘Squawk Box’ to discuss the U.S-China trade breakthrough, impact on the chips sector,…
“Apple in China,” by Patrick McGee, tells the gripping tale of how the computer giant’s decades-long investment in China fueled its spectacular success and, in…
Apple in China: The Capture of the World’s Greatest Company by Patrick McGee (Simon & Schuster) is out on Tuesday. Apple relied on cheap Chinese labour…